According to documents shared with The Washington Post, the Trump administration's confidential deals with pharmaceutical companies to lower U.S. drug prices include inducements to raise drug prices overseas and promise protection from President Donald Trump's tariffs. Pfizer Inc. has agreed to share a portion of its net increased revenue from charging higher drug prices abroad with the US Department of Health and Human Services. The contract, which was released on Saturday, applies to medicines already on the market and is effective from January 1, 2026, through January 20, 2029. However, the rate of revenue sharing, included medicines, and other details remain redacted in the publicly available documents. The provision is part of Pfizer's "most favored nation" drug-pricing agreement and represents a significant policy shift in how drugmakers approach global pricing strategies.
As reported by Business Standard, White House spokesperson Kush Desai stated that "President Trump has been very clear that this is not a one-way street: Foreign prices are going to increase and American patients are no longer going to solely bear the burden of funding global innovation." The foreign-revenue provisions are intended to ensure incremental revenue from higher prices abroad benefit American patients, not drugmakers. President Donald Trump emphasized during a recent Oval Office event that "Now, other countries are paying more so that Americans can pay less." The policy is designed so that additional income generated from higher foreign prices benefits American patients rather than drugmakers, creating a more equitable pricing structure.
Despite the redactions, Public Citizen's analysis reveals concerning provisions that benefit pharmaceutical companies over patients. The agreements contain secret conditions allowing drugmakers to withhold international pricing data required under MFN agreements when restricted by foreign laws. Pfizer's deal includes a provision that "if Pfizer is unable to provide international drug pricing data due to restrictions imposed by applicable foreign laws, Pfizer shall promptly notify CMS in writing, describing the nature of the restriction, the legal authority, and the affected data." Additionally, the agreements allow companies to avoid offering lower drug price points to Americans and hurt patients in other countries. Lilly's deal permits the company to stop supplying a drug to a reference country, notify the American government, and get that country's price point excluded from MFN price calculations. According to The Washington Post, the agreements include broad confidentiality clauses that limit transparency into the deal terms.
According to Business Standard, Pfizer spokesperson Amy Rose stated that the company stands "by our belief that the agreement Pfizer voluntarily reached with the administration last September is a win for American patients" and achieves priorities to lower prices for patients, redistribute global research and development costs, and create a predictable investment environment. However, Public Citizen's analysis reveals that the agreements may cause harm to patients in the U.S. and abroad. The documents show that Pfizer's compliance is not contingent on any state's participation in GENEROUS, meaning the company can still benefit from the deal even if states choose not to participate. The agreements also lack transparency on how U.S. health programs or patients get access to MFN pricing for newly launched drugs, with Lilly's deal stating it "does not include pricing obligations in the commercial channel." As reported by The Washington Post, the deals include tariff protections that shield drugmakers from potential trade policy changes.
As reported by Business Standard, the release provides additional detail about how the Trump administration's drug-pricing policy fits in with broader trade negotiations. The US and UK reached a trade agreement in December allowing tariff-free imports of medicines in exchange for a significant reduction in rebates drugmakers pay to the UK's National Health Service, with the UK government boosting spending on medicines by 25%. Documents related to a separate agreement with Eli Lilly were also released, though more than two dozen other drugmaker agreements remain confidential. The disclosures provide more detail on how the administration's effort to lower U.S. drug prices is tied to efforts to raise prices paid for medicines in overseas markets.
